Tumour lysis syndrome

Tumour Lysis Syndrome (TLS) is a critical oncological emergency caused by extensive tumor cell breakdown, releasing intracellular contents into the bloodstream faster than homeostatic mechanisms can manage.
TLS leads to metabolic imbalances, including hyperuricaemia, hyperkalaemia, hyperphosphataemia, and hypocalcaemia, posing risks of acute kidney injury, cardiac arrhythmias, seizures, organ failure, and death.
TLS typically occurs after effective cancer treatment, especially in patients with significant tumor burdens (≥500 g).
Prevention involves close monitoring, hydration, and prophylaxis with agents like rasburicase and allopurinol.
The clinical utility of xanthine measurement during treatment remains unclear.

TLS is a severe metabolic condition primarily triggered by the breakdown of bulky and highly proliferative tumors, with clinical consequences arising from massive cellular lysis.
Characterized by rapid release of intracellular content into circulation resulting in metabolic disturbances, notably hyperuricaemia, hyperkalaemia, hyperphosphataemia, and hypocalcaemia.
Succinctly defined by laboratory criteria and confirmed when clinical manifestations such as acute kidney injury and other organ failures occur.

Estimations of TLS incidence are complicated due to varying cancer types and treatments.
A notable increase in TLS incidence observed in studies, such as a rise from 16% to 23% between 2010 and 2013.
TLS reports have increased in malignancies previously thought to have low risk, like chronic lymphocytic leukaemia and multiple myeloma.
Most prevalent cancers linked to TLS include non-Hodgkin lymphoma, solid tumors, and leukemia.
Factors like advanced disease and metastatic cancers significantly heighten TLS risk.

Rapid tumor lysis overwhelms homeostatic mechanisms; pivotal electrolytes (potassium, phosphate) and uric acid surge into circulation.
Necrosis often occurs within the tumor tissue itself manifesting in microemboli and tissue damage.
Histones and cytokines released during TLS contribute to inflammation and renal injury.
Urine alkalinization previously used for uric acid solubility but risks calcium phosphate precipitation now emphasized against.

Diagnosis involves measuring serum electrolytes (potassium, phosphorus, calcium, uric acid) and renal function parameters.
Recommended vigilance even before starting therapy in high-risk patients.
Monitoring includes urine output, potential arrhythmias, and evaluating the need for inpatient versus outpatient management based on risk and presentation.

Hydration is critical to maintaining renal function and promoting diuresis.
Agents like allopurinol are used to decrease uric acid production unless risk of xanthine nephropathy due to bulky tumor mass is substantial.
Rasburicase is employed in high-risk scenarios for rapid reduction of uric acid due to its efficiency.
Monitoring for electrolyte imbalances and administration of appropriate replacement therapies for calcium and potassium when needed.

TLS exerts immediate adverse effects on patient quality of life and may lead to longer hospital stays with complications like acute kidney injury.
Long-term impacts associated with renal function decline heighten subsequent risks from nephrotoxic therapies and could markedly affect dose intensity and approach to cancer therapy.

Research needed to address current dilemmas surrounding the use of xanthine oxidase inhibitors, particularly regarding xanthine nephropathy and TLS management strategies in diverse settings.
Simplifying risk stratification frameworks essential for practical bedside application.
Emphasis on access to necessary medications and supportive care for timely management of TLS in differing socio-economic contexts.